Endologix

Endologix, Inc. is a developer and manufacturer of minimally invasive treatments for aortic disorders. We have over 850 employees and listed on NASDAQ (ELGX). Since launching in the U.S. in 2005, Endologix has experienced average annual growth of 60%+ and was the top performing med tech stock in 2009. The Company's Powerlink® System is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. More than 2 million people in the U.S. have AAA, with 200,000 new cases diagnosed every year. If left untreated, AAAs become increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the U.S.

Type
Public
HQ
Irvine, US
Size (employees)
782 (est)+27%
Endologix is headquartered in Irvine, US

Endologix Office Locations

Endologix has offices in Irvine and Rosmalen
Irvine, US (HQ)
2 Musick
Rosmalen, NL
40 Burgemeester Burgerslaan

Endologix Data and Metrics

Endologix Financial Metrics

Endologix's revenue was reported to be $192.9 m in FY, 2016 which is a 26% increase from the previous period.
USD

Revenue (FY, 2016)

192.9 m

Revenue growth (FY, 2015 - FY, 2016), %

26%

Gross profit (FY, 2016)

123.8 m

Gross profit margin (FY, 2016), %

64%

Net income (FY, 2016)

(154.7 m)

EBIT (FY, 2016)

(95.1 m)

Market capitalization (26-Jun-2017)

417.4 m

Closing share price (26-Jun-2017)

4.7

Cash (31-Dec-2016)

26.1 m
Endologix's current market capitalization is $417.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

132.3 m147.6 m153.6 m192.9 m

Revenue growth, %

12%4%26%

Cost of goods sold

41.8 m51.8 m69.1 m

Gross profit

99.5 m105.8 m101.8 m123.8 m

Gross profit Margin, %

75%72%66%64%

Operating expense total

109.9 m134.9 m154.7 m218.9 m

EBIT

(10.4 m)(29.1 m)(52.9 m)(95.1 m)

EBIT margin, %

(8%)(20%)(34%)(49%)

Interest expense

321 k5.7 m7.5 m15.8 m

Interest income

50 k245 k175 k228 k

Income tax expense

10 k62 k9.3 m(498 k)

Net Income

(16.1 m)(32.4 m)(50.4 m)(154.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

95.2 m26.8 m124.6 m26.1 m

Accounts Receivable

310 k498 k375 k1.8 m

Inventories

19.6 m31.3 m27.9 m41.2 m

Current Assets

173.6 m147.8 m237.5 m129.8 m

PP&E

7.3 m25.7 m23.4 m23.3 m

Goodwill

29.1 m28.9 m28.7 m120.7 m

Total Assets

256.2 m248.2 m335.8 m359.7 m

Accounts Payable

6.3 m11 m17.5 m13.2 m

Current Liabilities

67.3 m29.6 m50.9 m44.9 m

Additional Paid-in Capital

321.8 m372.6 m404.5 m567.8 m

Retained Earnings

(216.1 m)(248.5 m)(298.9 m)(453.6 m)

Total Equity

103.3 m112.8 m

Financial Leverage

3.3 x3.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(32.4 m)(50.4 m)(154.7 m)

Depreciation and Amortization

3.3 m5.9 m9.1 m

Inventories

(12 m)3.5 m3.5 m

Accounts Payable

2.7 m8.3 m(5.2 m)

Cash From Operating Activities

50 m(26.3 m)(31.1 m)(74.8 m)

Purchases of PP&E

(13.5 m)(4.2 m)(2.8 m)

Cash From Investing Activities

(43.3 m)2.9 m(28.5 m)

Cash From Financing Activities

2.1 m126.7 m5.3 m

Interest Paid

2 m2 m6.3 m

Income Taxes Paid

258 k124 k208 k
USDY, 2016

Revenue/Employee

311.7 k

Financial Leverage

3.2 x

Endologix Market Value History

Endologix Company Life and Culture

You may also be interested in